Zava OD 100 Tablet contains Vildagliptin 100 mg, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Vildagliptin enhances glycemic control by increasing the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. This mechanism helps improve both fasting and postprandial blood glucose levels without causing significant hypoglycemia. Zava OD 100 is typically prescribed as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin, to achieve optimal glycemic control in adults. The once-daily dosing regimen improves patient compliance and convenience. Clinical studies have demonstrated that Vildagliptin is well tolerated, with a low incidence of adverse effects, the most common being mild gastrointestinal disturbances and headache. It is contraindicated in patients with known hypersensitivity to the drug or its components. Caution is advised in patients with hepatic or renal impairment, and regular monitoring of liver enzymes and renal function is recommended during therapy. Zava OD 100 Tablet should be used as part of a comprehensive diabetes management plan, including diet and exercise, under the supervision of a healthcare professional.